Becton, Dickinson and Co. | BDX - Sales Revenues

Stock Price
180.96
Daily Change
-1.53 -0.84%
Monthly
-11.04%
Yearly
-20.49%
Q1 Forecast
179.64

Becton, Dickinson and Co. reported $5.3B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
Agilent USD 1.8B 63M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
AngioDynamics USD 72M 841K Feb/2025
Avanos Medical USD 180.9M 3.1M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Becton, Dickinson and Co. USD 5.3B 600M Dec/2025
Bio-Rad Laboratories USD 693.2M 40.2M Dec/2025
Boston Scientific USD 5.29B 220M Dec/2025
Cooper Companies USD 1.07B 4.9M Sep/2025
Danaher USD 6.84B 790M Dec/2025
Dentsply International USD 904M 32M Sep/2025
Dexcom USD 1.26B 50M Dec/2025
Edwards Lifesciences USD 1.57B 20M Dec/2025
Exact Sciences USD 878.38M 27.38M Dec/2025
Globus Medical USD 826.4M 57.4M Dec/2025
Hologic USD 1.05B 0 Dec/2025
Insulet USD 783.8M 77.5M Dec/2025
Integra LifeSciences USD 402.06M 13.54M Sep/2025
Intuitive Surgical USD 2.87B 360M Dec/2025
J&J USD 24.6B 610M Dec/2025
Masimo USD 371.5M 600K Sep/2025
Medtronic USD 9B 39M Jan/2026
Solventum Corp USD 2.1B 60M Sep/2025
Stryker USD 7.2B 1.14B Dec/2025
Tandem Diabetes Care USD 290.4M 41.15M Dec/2025
Teleflex USD 913M 132.11M Sep/2025
Terumo JPY 296.63B 21.66B Dec/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Zimmer Biomet Holdings USD 2.24B 240M Dec/2025